首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3113篇
  免费   313篇
  国内免费   58篇
耳鼻咽喉   36篇
儿科学   108篇
妇产科学   43篇
基础医学   389篇
口腔科学   61篇
临床医学   437篇
内科学   689篇
皮肤病学   196篇
神经病学   417篇
特种医学   137篇
外国民族医学   1篇
外科学   354篇
综合类   186篇
预防医学   181篇
眼科学   31篇
药学   165篇
  2篇
中国医学   21篇
肿瘤学   30篇
  2024年   3篇
  2023年   105篇
  2022年   91篇
  2021年   213篇
  2020年   200篇
  2019年   156篇
  2018年   187篇
  2017年   204篇
  2016年   135篇
  2015年   112篇
  2014年   230篇
  2013年   322篇
  2012年   144篇
  2011年   138篇
  2010年   130篇
  2009年   127篇
  2008年   138篇
  2007年   127篇
  2006年   114篇
  2005年   102篇
  2004年   97篇
  2003年   60篇
  2002年   52篇
  2001年   39篇
  2000年   35篇
  1999年   23篇
  1998年   28篇
  1997年   28篇
  1996年   27篇
  1995年   19篇
  1994年   20篇
  1993年   12篇
  1992年   9篇
  1991年   13篇
  1990年   7篇
  1989年   3篇
  1988年   5篇
  1987年   3篇
  1986年   4篇
  1985年   5篇
  1984年   6篇
  1983年   1篇
  1982年   1篇
  1981年   2篇
  1980年   1篇
  1978年   2篇
  1977年   1篇
  1974年   2篇
  1973年   1篇
排序方式: 共有3484条查询结果,搜索用时 15 毫秒
1.
目的 分析轻型/重型新型冠状病毒肺炎(COVID-19)患者的临床特征,探讨心肌型脂肪酸结合蛋白(H-FABP)与COVID-19轻重症的相关性。方法 回顾性分析2022年6月前重庆大学附属三峡医院收治的超敏肌钙蛋白T(hs-cTnT)表达阴性的COVID-19患者40例,根据《新型冠状病毒肺炎诊疗方案(试行第八版)》诊断标准,将患者分为轻型和重型两组,比较两组外周血中H-FABP表达水平差异。结果 符合纳入标准的COVID-19患者共40例,其中轻型组20例,重型组20例,与轻型组相比,重型组年龄更大[(41.9±10.5) vs (58.2±16.3)岁],且合并糖尿病比例更高(P均<0.05)。通过比较两组血清H-FABP表达水平发现,重型组H-FABP水平明显高于轻型组[(3.97±1.80) vs (6.88±3.90) μg/L,P<0.05]。结论 在hs-cTnT表达阴性的COVID-19患者中,血清H-FABP表达水平与COVID-19疾病严重程度相关,H-FABP可能作为一个更加敏感且独立的心肌损伤因子用于COVID-19疾病分型。  相似文献   
2.
PurposeTo evaluate the effectiveness and safety of fluoroscopy-guided percutaneous high ligation (FPHL) combined with fluoroscopy-guided foam sclerotherapy (FGFS) to treat varicose veins of the great saphenous veins (GSVs).Materials and MethodsThis was a retrospective study of 113 patients (mean age, 62.1 ± 10.8 years; 60 men) with varicose veins of the GSVs (133 limbs) that were treated with FPHL combined with FGFS between April 1 and October 31, 2019. Demographic and clinical data were collected from these patients before the FPHL procedure, after which FGFS was performed. The preterminal GSV was ligated percutaneously by a percutaneously-positioned polypropylene ligature under fluoroscopic guidance. The outcome of ligation was confirmed by venography. Then, foam sclerotherapy was performed under fluoroscopy. At 1-year follow-up, GSV occlusion was evaluated by ultrasound. The venous clinical severity scores (VCSSs) were compared between the preoperative and 1-year follow-up periods.ResultsThe technical success rate was 100% (133 limbs). Complete 12-month follow-up was available for 112 limbs (84.2%) and 103 of these limbs (92.0%) remained occluded during this period. The VCSS improved from 4.71 ± 2.15 to 0.74 ± 0.60 (V = 6328, P < .001). During follow-up, there were 16 limbs with thrombophlebitis and 38 limbs with saphenous junction pain; these events were alleviated within 2 weeks of the procedure. There was no deep venous thrombosis or other severe adverse events.ConclusionsFPHL combined with FGFS to treat varicose veins in the GSVs achieved an occlusion rate of 92% and improved the clinical symptoms within 1 year; this minimally-invasive procedure was safe and effective.  相似文献   
3.
目的探究老年2型糖尿病(T2DM)并阻塞性睡眠呼吸暂停综合征(OSAS)患者25羟基维生素D[25(OH)D]和血小板参数[平均血小板体积(MPV)和血小板分布宽度(PDW)]变化及与OSAS严重程度的相关性。方法选择2016年10月—2021年10月于宁德师范学院附属宁德市医院诊治的61例老年T2DM合并OSAS患者为观察组,50例单纯T2DM患者为对照组。观察并比较2组基线资料及血25(OH)D、MPV、PDW水平,以及OSAS严重程度不同的患者25(OH)D、MPV和PDW水平,采用Logistic回归模型分析OSAS的影响因素。结果 2组BMI、高血压史、冠心病史、糖化血红蛋白(HbA1c)、高密度脂蛋白胆固醇(HDL-C)和尿酸(UA)差异具有统计学意义(P<0.05);观察组MPV和PDW显著高于对照组(P<0.05),25(OH)D低于对照组(P<0.05);OSAS严重程度不同的患者间25 (OH)D和血小板参数差异具有统计学意义(P<0.05),其中25(OH)D随着OSAS严重程度的增高而降低(P<0.05),MPV、PDW随着OSAS严重程度的增高而上升(P<0.05);Logistic回归分析结果显示,冠心病史、HbA1c、25(OH)D、MPV和PDW是OSAS发生的影响因素(P<0.05)。结论老年T2DM合并OSAS患者MPV和PDW变化呈现上升趋势,25(OH)D呈下降趋势,其水平变化与T2DM合并OSAS发生和病情关系密切。  相似文献   
4.
5.
6.
BackgroundThe consistency in reporting the severity of drug interactions across the drug information resources is important in guiding the appropriate clinical use of drug-pairs, to minimize the associated adverse events. This necessitates the need of a standardized severity rating scale, that can accommodate the different severity ratings of the same interacting drug-pair into a reasonable severity category, that can ease the consistency assessment among different drug information resources.ObjectiveTo develop and validate a standardized severity rating scale that can ease the consistency assessment among the various drug information resources.MethodsThe definitions of various severity rating categories as documented in the eight drug information resources was consolidated to develop a standardized severity rating scale. Thus developed rating scale was validated using twenty commonly used drug-pairs. Fleiss' kappa score was used as an indicator for assessing overall consistency among various drug information resources, whereas, Cohen's kappa was used as an indicator of level of consistency between two drug information resources and between individual drug information resource and newly developed standardized severity rating scale.ResultsThe newly developed standardized severity rating scale classifies the severity of drug-drug interactions into three categories namely mild, moderate and major. The Fleiss' kappa score was improved from 0.047 to 0.176, indicating improved strength of agreement [Average pairwise agreement: 16% Vs 36.7%] among various drug information resources. The average pairwise Cohen's kappa was 0.082 [Strength of agreement: poor] in original severity ratings whereas it was improved to 0.198 [Strength of agreement: almost equal to fair] in standardized severity rating scale.ConclusionThe newly developed standardized severity rating scale can be used as a tool to assess the consistency of severity rating categories among the various drug information resources.  相似文献   
7.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has triggered a widespread outbreak since December 2019. The SARS-CoV-2 infection-related illness has been dubbed the coronavirus disease 2019 (COVID-19) by the World Health Organization. Asymptomatic and subclinical infections, a severe hyper-inflammatory state, and mortality are all examples of clinical signs. After attaching to the angiotensin converting enzyme 2 (ACE2) receptor, the SARS-CoV-2 virus can enter cells through membrane fusion and endocytosis. In addition to enabling viruses to cling to target cells, the connection between the spike protein (S-protein) of SARS-CoV-2 and ACE2 may potentially impair the functionality of ACE2. Blood pressure is controlled by ACE2, which catalyzes the hydrolysis of the active vasoconstrictor octapeptide angiotensin (Ang) II to the heptapeptide Ang-(1-7) and free L-Phe. Additionally, Ang I can be broken down by ACE2 into Ang-(1-9) and metabolized into Ang-(1-7). Numerous studies have demonstrated that circulating ACE2 (cACE2) and Ang-(1-7) have the ability to restore myocardial damage in a variety of cardiovascular diseases and have anti-inflammatory, antioxidant, anti-apoptotic, and anti-cardiomyocyte fibrosis actions. There have been some suggestions for raising ACE2 expression in COVID-19 patients, which might be used as a target for the creation of novel treatment therapies. With regard to this, SARS-CoV-2 is neutralized by soluble recombinant human ACE2 (hrsACE2), which binds the viral S-protein and reduces damage to a variety of organs, including the heart, kidneys, and lungs, by lowering Ang II concentrations and enhancing conversion to Ang-(1-7). This review aims to investigate how the presence of SARS-CoV-2 and cACE2 are related. Additionally, there will be discussion of a number of potential therapeutic approaches to tip the ACE/ACE-2 balance in favor of the ACE-2/Ang-(1-7) axis.  相似文献   
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号